Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine
This study has been completed.
Sponsor:
Janssen-Ortho LLC
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by:
Janssen-Ortho LLC
ClinicalTrials.gov Identifier:
NCT00210496
First received: September 13, 2005
Last updated: May 16, 2011
Last verified: April 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | June 2007 |
| Estimated Primary Completion Date: | No date given |